DNX 2401

Drug Profile

DNX 2401

Alternative Names: Ad-delta24-RGD; Ad-DNX 2401; Ad5-Delta 24RGD; Ad5-delta24-RGD; Adenovirus DNX 2401; Adenovirus-5 delta 24 RGD; Delta 24 RGD 4C; Delta-24-RGD; Delta-24-RGDOX; DNX-2401; IE-CRAd; RGD-delta24; VLI-01A

Latest Information Update: 10 Nov 2016

Price : $50

At a glance

  • Originator DNAtrix; University of Texas M. D. Anderson Cancer Center
  • Developer Clinica Universidad de Navarra; DNAtrix; Merck & Co; University of Alabama Comprehensive Cancer Center
  • Class Cancer vaccines; DNA vaccines; Oncolytic viruses
  • Mechanism of Action Cell death stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Glioblastoma
  • New Molecular Entity No

Highest Development Phases

  • Phase II Glioblastoma; Glioma
  • No development reported Ovarian cancer

Most Recent Events

  • 03 Nov 2016 Phase-I clinical trials in Glioma (Newly diagnosed, In children, In adolescents, First-line therapy) in Spain (Intratumoural) (EudraCT2016-001577-33)
  • 12 Sep 2016 Phase I development is ongoing in Glioblastoma (Combination therapy, Recurrent, Second-line therapy or greater) USA (Intratumoural, Injection) (NCT02197169)
  • 12 Sep 2016 DNAtrix Therapeutics plans a phase III trial for Glioblastoma (Monotherapy) in USA (DNAtrix Therapeutics pipeline, September 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top